Format
Sort by
Items per page

Send to

Choose Destination

Links from Gene

Items: 1 to 20 of 420

1.

Discordant prostate specific antigen test results despite WHO assay standardization.

Boegemann M, Arsov C, Hadaschik B, Herkommer K, Imkamp F, Nofer JR, Gerß J, Albers P, Semjonow A.

Int J Biol Markers. 2018 Aug;33(3):275-282. doi: 10.1177/1724600818754750. Epub 2018 May 8.

PMID:
29734838
2.

Prostate-specific antigen associates with extensive lymph node invasion in high-risk prostate cancer.

Porcaro AB, Corsi P, Inverardi D, Sebben M, Tafuri A, Processali T, Mattevi D, De Marchi D, Pirozzi M, Cerruto MA, Amigoni N, Rizzetto R, Brunelli M, Siracusano S, Artibani W.

Tumori. 2018 Aug;104(4):307-311. doi: 10.1177/0300891618765567. Epub 2018 Apr 6.

PMID:
29714659
3.

Label-free photoelectrochemical aptasensor for tetracycline detection based on cerium doped CdS sensitized BiYWO6.

Han Q, Wang R, Xing B, Chi H, Wu D, Wei Q.

Biosens Bioelectron. 2018 May 30;106:7-13. doi: 10.1016/j.bios.2018.01.051. Epub 2018 Jan 31.

PMID:
29414091
4.

Prostate-specific antigen (PSA) density in the diagnostic algorithm of prostate cancer.

Nordström T, Akre O, Aly M, Grönberg H, Eklund M.

Prostate Cancer Prostatic Dis. 2018 Apr;21(1):57-63. doi: 10.1038/s41391-017-0024-7. Epub 2017 Dec 19.

PMID:
29259293
5.

Superwettable microchips with improved spot homogeneity toward sensitive biosensing.

Chen Y, Xu LP, Meng J, Deng S, Ma L, Zhang S, Zhang X, Wang S.

Biosens Bioelectron. 2018 Apr 15;102:418-424. doi: 10.1016/j.bios.2017.11.036. Epub 2017 Nov 21.

PMID:
29175217
6.

Detection of early stage prostate cancer by using a simple carbon nanotube@paper biosensor.

Ji S, Lee M, Kim D.

Biosens Bioelectron. 2018 Apr 15;102:345-350. doi: 10.1016/j.bios.2017.11.035. Epub 2017 Nov 10.

PMID:
29172142
7.
8.

Increased PSA expression on prostate cancer exosomes in in vitro condition and in cancer patients.

Logozzi M, Angelini DF, Iessi E, Mizzoni D, Di Raimo R, Federici C, Lugini L, Borsellino G, Gentilucci A, Pierella F, Marzio V, Sciarra A, Battistini L, Fais S.

Cancer Lett. 2017 Sep 10;403:318-329. doi: 10.1016/j.canlet.2017.06.036. Epub 2017 Jul 8.

PMID:
28694142
9.

PSA declines and survival in patients with metastatic castration-resistant prostate cancer treated with enzalutamide: A retrospective case-report study.

Bosso D, Pagliuca M, Sonpavde G, Pond G, Lucarelli G, Rossetti S, Facchini G, Scagliarini S, Cartenì G, Daniele B, Morelli F, Ferro M, Puglia L, Izzo M, Montanaro V, Bellelli T, Vitrone F, De Placido S, Buonerba C, Di Lorenzo G.

Medicine (Baltimore). 2017 Jun;96(24):e6817. doi: 10.1097/MD.0000000000006817.

10.

Chronic Periodontitis Does Not Impact Serum Levels of Prostate-specific Antigen.

Kruck S, Hennenlotter J, Amend B, Geiger M, Filipova E, Neumann T, Stühler V, Schubert T, Todenhöfer T, Rausch S, Huettig F, Stenzl A, Bedke J.

Anticancer Res. 2017 Jun;37(6):3163-3167.

PMID:
28551659
11.

Genetic association between PSA-158G/A polymorphism and the susceptibility of benign prostatic hyperplasia: a meta-analysis.

Su XJ, Zeng XT, Fang C, Liu TZ, Wang XH.

Oncotarget. 2017 May 16;8(20):33953-33960. doi: 10.18632/oncotarget.15424. Review.

12.
13.

Safety and Antitumor Activity of Apalutamide (ARN-509) in Metastatic Castration-Resistant Prostate Cancer with and without Prior Abiraterone Acetate and Prednisone.

Rathkopf DE, Antonarakis ES, Shore ND, Tutrone RF, Alumkal JJ, Ryan CJ, Saleh M, Hauke RJ, Bandekar R, Maneval EC, de Boer CJ, Yu MK, Scher HI.

Clin Cancer Res. 2017 Jul 15;23(14):3544-3551. doi: 10.1158/1078-0432.CCR-16-2509. Epub 2017 Feb 17.

14.

Radiographic progression with nonrising PSA in metastatic castration-resistant prostate cancer: post hoc analysis of PREVAIL.

Bryce AH, Alumkal JJ, Armstrong A, Higano CS, Iversen P, Sternberg CN, Rathkopf D, Loriot Y, de Bono J, Tombal B, Abhyankar S, Lin P, Krivoshik A, Phung D, Beer TM.

Prostate Cancer Prostatic Dis. 2017 Jun;20(2):221-227. doi: 10.1038/pcan.2016.71. Epub 2017 Jan 24.

15.

The impact of comorbidity and PSA doubling time on the risk of death in men experiencing PSA failure following radiation therapy with or with androgen deprivation therapy for unfavorable-risk prostate cancer.

Patel SA, Chen MH, Loffredo M, Renshaw A, Kantoff PW, D'Amico AV.

Prostate Cancer Prostatic Dis. 2017 Jun;20(2):234-240. doi: 10.1038/pcan.2016.74. Epub 2017 Jan 24.

PMID:
28117382
16.

End-of-radiation PSA as a novel prognostic factor in patients undergoing definitive radiation and androgen deprivation therapy for prostate cancer.

Narang AK, Trieu J, Radwan N, Ram A, Robertson SP, He P, Gergis C, Griffith E, Singh H, DeWeese TA, Honig S, Annadanam A, Greco S, DeVille C, McNutt T, DeWeese TL, Song DY, Tran PT.

Prostate Cancer Prostatic Dis. 2017 Jun;20(2):203-209. doi: 10.1038/pcan.2016.67. Epub 2017 Jan 17.

17.

Unscreened older men diagnosed with prostate cancer are at increased risk of aggressive disease.

Tosoian JJ, Alam R, Gergis C, Narang A, Radwan N, Robertson S, McNutt T, Ross AE, Song DY, DeWeese TL, Tran PT, Walsh PC.

Prostate Cancer Prostatic Dis. 2017 Jun;20(2):193-196. doi: 10.1038/pcan.2016.64. Epub 2017 Jan 3.

18.

Risk assessment models to evaluate the necessity of prostate biopsies in North Chinese patients with 4-50 ng/mL PSA.

Zhao J, Liu S, Gao D, Ding S, Niu Z, Zhang H, Huang Z, Qiu J, Li Q, Li N, Xie F, Cui J, Lu J.

Oncotarget. 2017 Feb 7;8(6):9935-9946. doi: 10.18632/oncotarget.14214.

19.

Detection of Prostate Cancer Metastasis by Whole Body Magnetic Resonance Imaging Combined with Bone Scintigraphy and PSA Levels.

An H, Tao N, Li J, Guan Y, Wang W, Wang Y, Wang F.

Cell Physiol Biochem. 2016;40(5):1052-1062. Epub 2016 Dec 12.

20.

Extended mortality results for prostate cancer screening in the PLCO trial with median follow-up of 15 years.

Pinsky PF, Prorok PC, Yu K, Kramer BS, Black A, Gohagan JK, Crawford ED, Grubb RL, Andriole GL.

Cancer. 2017 Feb 15;123(4):592-599. doi: 10.1002/cncr.30474. Epub 2016 Dec 1.

Supplemental Content

Support Center